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INTRODUCTION
Much of the earliest work in microbiology, largely performed in the 17th-18th centuries, included microscopic observations of the diverse microbes in human tissues and excretions [1] . Medical microbiology, a field that has largely existed for the past century and a half, built on those early studies by focusing on the identification, cultivation, and analysis of specific microbial 'pathogens'. This 'pathogen-oriented' approach, although enormously helpful and successful for many diseases, often ignored the presence and activities of the numerous other microbes that we now know to inhabit us. Many statements published throughout the 20th-century literature attest to the general sterility of healthy human airways, tacitly asserting that mechanisms must exist to filter or clear the copious microbes inhaled during normal respiration ( [2] and references therein). Meanwhile, in the gastrointestinal tract, comparisons of the bacteria identified in human fecal samples using microscopic versus cultivation-based methods revealed striking disparities in the types and abundances of microbes present [3, 4] . Thus, in these two organs -the lung and the gastrointestinal tractthere were discrepancies between what was observed using culture (the absence of microbes in airways, the balance of bacteria in stools) and what was expected based on other considerations (constant inhalation of microbes, the microscopic analyses of stools).
In the mid-20th century, remarkably similar observations were made by environmental microbiologists comparing microscopic findings with routine culture of aquatic specimens. These studies identified major discrepancies in microbial content now collectively referred to as 'the great plate count anomaly' [5] . Such discordances underscored the inadequacies of routine culture techniques (which, it is now generally accepted, easily identify only $1% of known bacteria) [6] and led to the adaptation, refinement, and application of 'culture-independent' microbiological techniques that do not rely on microbial growth, but rather detect their molecular signatures (most often their genetic material). It was only a matter of time before medical microbiologists would take notice of these advances. These newer techniques, often referred to as microbiome methods, have provided fascinating new findings that have forced us to revise our notions of how microbes inhabit our bodies in various states of health. Our models of how these microbiota promote health and cause disease are continuously updated as fresh data become available.
In this review, we will briefly describe these new techniques, and the current view they have afforded of both lung and gastrointestinal microbiomes in pediatric respiratory health. Although most of the research in this area has been performed in people with cystic fibrosis (CF) and asthma, the implications for other diseases, and for healthy mucosal surfaces, are also discussed. Although this article will occasionally (and necessarily) include technical details, our hope is to briefly and simply illustrate how recent technological advances have 'pulled back the curtain' on our internal microbiological world, revealing a new view of pediatric respiratory health and disease pathogenesis. Before reviewing these recent advances, we will first define some of the most common, and often most confusing, terms and techniques used in the microbiome field.
DEFINITIONS
The term microbiome, originally coined by microbiologist Joshua Lederberg, signifies the 'community of commensal, symbiotic, and pathogenic microorganisms that . . . share our body space' [7] . 'Microbiome' can be more succinctly defined as 'the totality of microbes, their genes, and their interactions in a given environment' [8], therefore referring to not only 'who's there' but also 'what they can do'. By contrast, the term 'microbiota' refers only to the actual microorganisms that are found in a particular location ('niche') in the human body [9 && ] (or 'who's there'). Therefore, because much of what we consider to be 'microbiome' research often focuses on identifying the microbes in a niche, 'microbiota' is probably a more accurate term for many studies. For simplicity, however, and in keeping with common practice, we will use the term 'microbiome' to refer to most research in this review. Furthermore, although a microbiome technically includes all microbe types -viruses, bacteria, fungi, and others -most studies thus far have focused solely on bacteria. For this reason, much of the following discussion similarly focuses on bacteria, acknowledging that more work must be done to characterize the fungal and viral contributions to the human microbiome.
Microbiomes are frequently very complex with respect to the identities and abundances of specific microbes. For this reason, comparing microbiomes from different sources can be difficult, and statistical descriptors have been developed for the simplified characterization and comparison of microbiomes. For example, 'richness' refers to the number of different species present in a microbiome, 'evenness' is the degree to which those species are of equal abundance, and 'dominance' is the extent to which one or more species is numerically superior [9 && ]. These concepts and measures make it relatively straightforward to compare microbiomes from different people or anatomic locations, and to describe changes within one microbiome under stress or perturbation, such as with disease or medical treatments [10] . These situations are often accompanied by dysbiosis, an imbalance in the microbes present in a particular niche that can frequently be found with changes in health [9 && ].
KEY POINTS
Thanks to advances in sequencing technologies, it is now known that healthy and diseased lungs contain diverse microbes that are often not identified by traditional culture methods.
The relationship between lung microbes and disease is a topic of intense research.
These same technologies have also provided evidence that the microbiota in the gastrointestinal tract can impact the development and severity of lung diseases such as asthma.
Continued research on the microbiomes of the lung and gastrointestinal tract in health and disease will clarify the microbial contributions to the pathogenesis of diverse diseases, and may lead to improved treatments.
METHODS
As noted in the previous section, new molecular diagnostic techniques have revealed that traditional cultures only identify a small percentage of the microbes present in the airway [11, 12] . Several methods have been used to more comprehensively define microbial community membership, each of which has advantages, disadvantages, and potential biases or errors, which will be briefly described here but have been reviewed in detail elsewhere [13 & ]. Real-time quantitative PCR remains the most common technique for amplifying and quantifying abundances of specific DNA or RNA sequences. To elucidate spatial characteristics and abundances of organisms in clinical specimens, fluorescence in-situ hybridization (FISH) can be performed. This technique uses fluorescently labeled probes for specific bacterial sequences, followed by fluorescent microscopy to identify their targets and localize them within tissues.
Most microbiome research has relied on techniques that identify and characterize a gene carried by all bacteria, the 16S ribosomal RNA (rRNA) gene. This gene contains some sequences that are well conserved among bacteria (allowing for identification of a cell as a bacterium) and others that are highly variable (allowing for identification of specific bacterial types, or taxa, often at the phylum, genus, or species level); it is this quality of mixed sequence conservation that makes this gene so useful for bacterial taxonomic identification [14] . Once the DNA is purified from a sample of interest, PCR is usually used to amplify a large portion of the rRNA gene using primers targeting conserved regions (i.e., to generate a pool of 16S rRNA 'amplicons'the amplified rRNA genes -from all detectable bacteria), and then various methods are used to probe or sequence the variable regions of those amplicons to identify and quantify specific taxa. Over the past several decades, this work has revealed many previously uncultured bacteria [15] .
In the earliest days of microbiome research, gel electrophoretic methods were most often used to define the microbial diversity of samples. These methods generally provide a qualitative 'footprint' of microbiomes, allowing for the comparison of microbial communities between different samples, but providing relatively limited quantitative or taxonomic information relative to newer sequencing techniques. Denaturing gradient gel electrophoresis (DGGE) and terminal restriction fragment length polymorphism (T-RFLP) analyses exploit the differences in rRNA amplicon sequences to provide these types of 'footprints'.
Recently, the gradually wider availability and dropping costs of next-generation sequencing have dramatically changed the field, generally supplanting other techniques. High-throughput sequencing of 16S rRNA gene amplicons, followed by computational comparison of the resulting sequence 'reads' to taxonomic databases, has yielded highresolution snapshots of microbiomes [13 & ]. With phylogenetic microarrays, such as the 16S rRNA PhyloChip (Second Genome, San Bruno, CA, USA), microbiomes are characterized by hybridizing their 16S amplicons to arrays of taxon-specific probes. The information provided is similar to that available from sequencing, with some differences in specificity and quantitative capacity, but that is limited to the probes available [16] . Sophisticated and powerful computational algorithms are required to analyze the sequence data, thus far limiting these techniques largely to research rather than clinical practice.
On the cutting edge are metagenomic techniques, which sequence all of the DNA (not just the 16S rRNA gene) in a specimen [13 & ]. Various computational methods can then be used to focus on the microbial sequences in the resulting data, allowing for the identification of not only bacteria but also fungi, viruses (again, 'who's there'), as well as the specific genes or gene classes that they carry ('what they can do'). These developing technologies show promise as the next step toward comprehensively defining the biology of the lung.
LUNG MICROBIOME
By comparison with traditional culture methods, culture-independent techniques have revealed surprisingly diverse bacterial microbiomes in the respiratory tracts of even healthy humans [17, 18] . Thus far, most respiratory microbiome analyses have been performed on bronchoalveolar fluid, oropharyngeal swabs, or sputum. Because bronchoscopes and sputum must traverse the upper airway, and oropharyngeal swabs directly target an upper airway site, it is difficult to predict a priori how accurately and specifically these specimens reflect lower airway microbiology. Recently, studies that directly analyzed CF lung tissue have identified diverse microbiomes [19] [20] [21] and found that upper and lower respiratory tracts have distinct but related microbiomes [14, 22] . In adults with end-stage CF lung disease, oropharyngeal swabs were shown to reflect lung tissue microbiomes poorly, while sputum did so somewhat more accurately [19, 23] . Similarly, lung tissue from a toddler with CF contained diverse and anatomically variable populations of microorganisms, indicating a high degree of spatial heterogeneity in early CF lung disease, and little similarity between lung tissue and oropharyngeal microbiomes [24 && ]. These findings provide a view of the respiratory tract as an anatomically heterogenous ecosystem stretching from the nares to the most distal airways, providing a diversity of niches for microbes. The microbiome compositions on these surfaces are likely determined by several factors, including rates of microbial immigration or delivery by inhalation; microbial elimination by cough, mucociliary clearance, or immunity; local physicochemical characteristics; the relative microbial growth rates; and interactions between different microbes [17] . As all of these characteristics may change over time, with different disease states and treatments, or among anatomic locations, so may the respiratory microbiota. These findings and considerations underscore the early state of lung microbiome research and the need for more work to better understand the determinants and consequences of microbiome composition within healthy lungs. However, respiratory microbiome research owes its origins to studies of respiratory diseases, with CF accounting for the lion's share of studies, followed by chronic obstructive lung disease, asthma, non-CF bronchiectasis, and other generally obstructive diseases.
CYSTIC FIBROSIS
The role of microbes in CF lung disease has been a topic of intense research and therapeutic importance since the earliest descriptions of this disorder [25] , and it is fitting that the earliest respiratory microbiome research focused on CF. The airway surfaces of people with CF have compromised mucociliary clearance and altered local antimicrobial activities, usually leading to chronic bacterial infection and inflammation [26] [27] [28] .
Antibiotic treatment has improved the quality of life and survival for people with CF, generally targeting a small group of bacterial species traditionally associated with CF pulmonary disease, including Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae, and Burkholderia cepacia complex [29] . One might therefore hypothesize that respiratory symptoms derive from an increased burden of these culturable pathogens [30] . However, neither the respiratory specimen densities of traditional CF pathogens nor of all bacteria have been found to reproducibly correlate with disease severity or symptomatic changes [31, 32] . Many children with CF exacerbations requiring intravenous antibiotics do not have culturable pathogens [32] , and although treatment with antibiotics has been associated with clinical improvement [33] , research has not identified a significant relationship between clinical response and the in-vitro susceptibilities of cultured bacteria [34, 35] . These observations further highlight the limited understanding of CF lung disease pathogenesis provided by the identification and therapeutic targeting of traditional pathogens, prompting a great deal of interest in microbiomeoriented approaches to CF lung disease.
Early studies used T-RFLP to examine sputum from adults with CF. These studies provided ample, reproducible evidence for diverse microbes, many not identified by clinical cultures. Since then, dozens of studies using progressively advanced methods have confirmed, clarified, and expanded those findings (reviewed in [36] ), and ongoing research continues to investigate how microbes relate to CF lung disease progression, and the impact of antibiotics [37] . In short, there is abundant evidence that CF airway microbiomes frequently include bacteria, such as obligate and facultative anaerobes, that are not readily cultured with standard techniques [11,38, 39 && ,40] .
Relatively few studies of CF respiratory microbiomes have focused on children. Existing evidence suggests that pediatric airway microbiomes initially increase in diversity, peak in early adulthood, and then decline [16] . This decline in diversity has been associated with more severe lung disease [40] , both of which are in turn associated with increased antibiotic treatment burden [40] [41] [42] [43] . Although studies have attempted to define a reliable microbiome 'marker' heralding the onset of CF respiratory exacerbations, no universal or reproducible biomarker has been identified [39 && ]. Therefore, the relationships between disease severity, respiratory microbiomes, and antibiotics must be clarified by longitudinal, modeling or interventional studies (Fig. 1 ).
NON-CYSTIC FIBROSIS PEDIATRIC LUNG DISEASES
In addition to CF, other chronic respiratory diseases -including asthma, non-CF bronchiectasis, and primary ciliary dyskinesia -have also been characterized using microbiome methods. This collective research has revealed remarkable parallels between the observations from CF and other airway diseases. The limited pediatric respiratory microbiome research to date has emphasized the importance of studying the earliest stages of disease development to understand pathogenesis. One recent study [44 && ] compared sputum and bronchoalveolar lavage microbiota among children with three different chronic airway diseases: CF, non-CF bronchiectasis, and protracted bacterial bronchitis. The 'core' microbiota (the most common and abundant bacteria) for each group were remarkably similar among all children but were different in adults with the same diagnoses. As with other studies [18, [45] [46] [47] , specimens from 'controls' without airway disease also had identifiable microbiota, but the focus on children here afforded a new finding: core respiratory microbiota that overlapped in health and early disease. These findings suggest a model in which all children have diverse airway microbiota that can change over time with disease.
Although the lung diseases discussed previously have customarily been associated with infection, the role of airway microbes in asthma is less well understood. Although asthma exacerbations are strongly associated with viral respiratory infections [17] , until recently very few studies examined the relationship between asthma and other microbes in the respiratory tract. It was recently shown that airway specimens from patients with asthma have distinct bacterial microbiota from those of healthy people, suggesting an association between respiratory microorganisms, airway inflammation, disease control, and even susceptibility to exacerbations [17, 48, 49] . One study comparing the respiratory specimen microbiota of poorly controlled asthmatic patients to controls found increased bacterial burdens and bacterial diversity among asthmatic patients, showing a correlation between diverse bacterial species and severity of bronchial hyperresponsiveness [49] . Another study identified a relationship between patients' baseline microbiota compositions and their clinical responses to systemic corticosteroids [50 && ]. However, as with CF, much more work will be needed to define the causal relationships between asthma disease severity, treatments (such as steroids), and airway microbiota. Nevertheless, the similarities that are emerging from respiratory microbiome research in different diseases are instructive. For example, airway microbiota do generally change yet remain remarkably complex during acute exacerbations of all of the above chronic inflammatory respiratory conditions. These observations contrast with what would be predicted according to pathogen-oriented models, wherein one bacterium invades or overtakes the local microbiota; instead, exacerbations may be caused by dysbiosis or disruptions in microbiome structures or behaviors.
GASTROINTESTINAL MICROBIOTA AND LUNG DISEASES
Increasing evidence implicates the gastrointestinal microbiome in key developmental, metabolic, and immunologic activities that, in turn, impact the development of respiratory disease. The gut microbiome dramatically increases in diversity in the first 3 years of life, stabilizing thereafter [51] . Cultureindependent methods have demonstrated that the mode of delivery at birth, diet, and antibiotic use affect the pattern of infant gut colonization [52] [53] [54] [55] .
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Microbiome Airway health FIGURE 1 . A schematic illustrating how many features of pediatric lung disease interact, confounding researchers' attempts to understand how microbiomes relate to disease symptoms and severity. For example, treatments such as steroids and antibiotics given to children with more severe disease can alter airway immunity, which may alter the observed microbiome. Alternatively, different microbiomes may lead to worse disease, leading to treatment with those medications. Unravelling these causal relationships is a notoriously difficult but critical step in identifying effective treatments targeting the microbiome.
A growing body of literature suggests that the gastrointestinal microbiome impacts the developing immune system and later health outcomes. For example, the gastrointestinal microbiome appears to play a vital role in the development and severity of a range of allergic diseases, including asthma, suggesting a mechanistic connection between gastrointestinal microbiomes and health of the airway and other mucosal surfaces [56, 57] . Clinical studies [56] have shown that early infant exposures known to alter infant gut microbiomes were associated with increased risks of asthma and eczema. However, other exposures, including dog-associated household dust, were associated with distinct gastrointestinal microbiota and decreased risk of atopic disease [58 && ]. These results provide an emerging view of a complex relationship between early exposures, gastrointestinal microbiomes, and atopic diseases such as asthma.
Another example of a relationship between the gastrointestinal system and respiratory disease comes from studies of children with CF. Early nutritional status in CF has been correlated with later severity of lung disease and overall survival [59 & ]. Recent work has identified a marked fecal dysbiosis in the pediatric CF gut microbiota characterized by greater abundances of Escherichia coli when compared with controls, irrespective of antibiotic exposure, and correlating with markers for gastrointestinal dysfunction [60] . A longitudinal study found that bacteria in the gastrointestinal microbiomes of infants with CF tend to appear later in their oropharyngeal microbiomes, suggesting the gastrointestinal tract may serve as a reservoir for respiratory infection [55] . Further linking gastrointestinal and respiratory health, clinical trials of probiotics in patients with CF have demonstrated improvements in gastrointestinal inflammation, lung function, and decreased rates of pulmonary exacerbations [61] [62] [63] . Therefore, the gastrointestinal microbiome offers an enticing target for modifying respiratory microbiology and health.
CONCLUSION
It is now clear that, even in healthy children, diverse communities of microbes inhabit tissue surfaces exposed to the environment, including the airways and gastrointestinal tract. With regard to the sites relevant to lung disease, the bulk of human microbiome research in the past decade has largely focused on tabulating 'who's there' -the types of microbes in these sites and how they vary between similar and different people, within a single person over time, and with perturbations such as diseases and medical treatments. The challenge we now face is to define how these microbiomes relate to health and disease: specifically, what roles do our microbes play in the natural development and health of our mucosal surfaces? To what extent do the medications we give in response to disease (e.g., antibiotics and steroids) account for the changes we observe? As in the past century, answering these questions will involve surprising findings, revisions of prevailing models, and the aid of ever-advancing technologies.
Future of the field
The next decade will likely see a great deal of transformative research, and hopefully new insights, in these critical areas of causality (Fig. 1) . The impact of treatments that promote 'healthy' microbiota, such as probiotics, prebiotics, and even interperson microbial transfers, on disease pathogenesis are a topic of intense interest. We may thus identify novel, rational ways to shape the microbiota of our young patients in ways that will promote or restore their respiratory health. One fascinating side benefit likely to result from this quest for better therapies is a more complete understanding of the microbes that rapidly colonize our bodies, and how to distinguish between beneficial and detrimental microbe-host relationships. 
